Company to showcase its innovative Alzheimer’s, Parkinson’s and ALS programs
TORONTO and CAMBRIDGE, Mass., Jan. 17, 2019 (GLOBE NEWSWIRE) — ProMIS Neurosciences, Inc. (TSX: PMN) (OTCQB: ARFXF), a biotechnology company focused on the discovery and development of antibody therapeutics selectively targeting toxic oligomers implicated in the development of neurodegenerative diseases, announced that it will participate in the NobleCon15 and the CanTech Investment Conferences. Members of ProMIS’ senior management will provide overviews of its novel drug discovery and development programs for Alzheimer’s disease, Parkinson’s disease and ALS (amyotrophic lateral sclerosis), and participate on discussion panels.
NobleCon15 Investor Conference – Eugene Williams, ProMIS’ Executive Chairman will present the company to investors on Monday, January 28, 2019 at 2:30pm, EST, at the W Hotel, Fort Lauderdale, Florida. In addition, James Kupiec, MD, ProMIS’ Chief Medical Officer will participate on a panel titled Researching the Cause of Alzheimer’s Disease – Quest for a Cure at 5:30pm EST on Monday, January 28, 2019.
A high definition, video webcast of the Mr. Williams’ presentation will be available the following day on the Company’s web site www.promisneurosciences.com, and on Noble Capital Markets’ websites: www.noblecapitalmarkets.com, and www.nobleconference.com. The webcast and presentation will be archived on the company’s website and on the Noble websites for 90 days following the event.
CanTech Investment Conference – Dr. Elliot Goldstein, ProMIS’ President and CEO will participate on a panel titled Biotech Solutions to a Neurodegenerative Crisis, on Tuesday, January 29, 2019 at 1:30pm EST. Following the panel discussion, Dr. Goldstein will present the company to investors at 2:40pm, EST. The conference is being held at the Metro Toronto Convention Centre, Toronto, Ontario.
About ProMIS’ Platform Technology
Numerous studies show that a common root cause of neurodegenerative diseases is the toxic oligomer, a misfolded protein that derives from naturally occurring proteins in the brain. Using its novel drug discovery platform, ProMIS can uniquely and selectively target the toxic oligomer, filling a critical gap for drug developers as traditional approaches to developing antibodies are unable to isolate and target the toxic oligomer with adequate precision. This proprietary platform can identify targets to produce, test and advance antibody candidates quickly and cost-effectively. ProMIS’ lead candidate antibody, PMN310 for Alzheimer’s disease, demonstrates a high degree of binding to toxic oligomers without binding to non-toxic forms of naturally occurring amyloid beta protein. The company’s program for Parkinson’s disease is based on the development of several potential antibody therapeutic candidates aimed at selectively targeting toxic oligomers of the protein α-synuclein, considered a root cause of Parkinson’s disease. Similarly, ProMIS has identified antibody candidates selectively targeting toxic oligomers of the protein TDP43, considered a root cause of ALS.
About ProMIS Neurosciences
ProMIS Neurosciences, Inc. is a development stage biotechnology company focused on discovering and developing antibody therapeutics selectively targeting toxic oligomers implicated in the development and progression of neurodegenerative diseases, in particular Alzheimer’s disease (AD), amyotrophic lateral sclerosis (ALS) and Parkinson’s disease (PD). The Company’s proprietary target discovery engine is based on the use of two complementary techniques. The Company applies its thermodynamic, computational discovery platform -ProMIS and Collective Coordinates – to predict novel targets known as Disease Specific Epitopes on the molecular surface of misfolded proteins. Using this unique precision medicine approach, the Company is developing novel antibody therapeutics for AD, ALS and PD. ProMIS is headquartered in Toronto, Ontario, with offices in Cambridge, Massachusetts. ProMIS is listed on the Toronto Stock Exchange under the symbol PMN, and on the OTCQB Venture Market under the symbol ARFXF.
Visit us at www.promisneurosciences.com or follow us on Twitter and LinkedIn
For media inquiries, please contact:
Shanti Skiffington
[email protected]
Tel. 617 921-0808
For Investor Relations please contact:
Alpine Equity Advisors
Nicholas Rigopulos, President
[email protected]
Tel. 617 901-0785
The TSX has not reviewed and does not accept responsibility for the adequacy or accuracy of this release. This information release contains certain forward-looking information. Such information involves known and unknown risks, uncertainties and other factors that may cause actual results, performance or achievements to be materially different from those implied by statements herein, and therefore these statements should not be read as guarantees of future performance or results. All forward-looking statements are based on the Company’s current beliefs as well as assumptions made by and information currently available to it as well as other factors. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date of this press release. Due to risks and uncertainties, including the risks and uncertainties identified by the Company in its public securities filings, actual events may differ materially from current expectations. The Company disclaims any intention or obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
